# Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

> **NCT01994629** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 202 (actual)

## Conditions studied

- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** MenACWY-CRM
- **BIOLOGICAL:** MenACWY-TT

## Key facts

- **NCT ID:** NCT01994629
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-04
- **Final completion:** 2014-10
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2015-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01994629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01994629, "Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01994629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*